Drug – bio-affecting and body treating compositions – Effervescent or pressurized fluid containing
Reexamination Certificate
2011-05-17
2011-05-17
Woodward, Cherie M (Department: 1619)
Drug, bio-affecting and body treating compositions
Effervescent or pressurized fluid containing
C514S038000, C514S040000, C514S041000, C514S075000, C514S099000, C514S851000, C436S017000, C424S045000, C424S046000
Reexamination Certificate
active
07943118
ABSTRACT:
A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having a mass median aerodynamic diameter predominantly between 1 to 5μ, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler.
REFERENCES:
patent: 5488038 (1996-01-01), Kondo et al.
patent: 5508269 (1996-04-01), Smith et al.
patent: 5618795 (1997-04-01), Kondo et al.
patent: 6083922 (2000-07-01), Montgomery
patent: 6387886 (2002-05-01), Montgomery et al.
patent: 6413946 (2002-07-01), Niizato et al.
patent: 6440951 (2002-08-01), Niizato et al.
patent: 6890907 (2005-05-01), Speirs et al.
patent: 2002/0061281 (2002-05-01), Osbakken et al.
patent: 2002/0187106 (2002-12-01), Weers et al.
patent: 2003/0191051 (2003-10-01), Needleman et al.
patent: 2005/0163722 (2005-07-01), Malvolti et al.
patent: 2006/0062738 (2006-03-01), Hofmann et al.
patent: 2001283491 (2002-01-01), None
patent: 57-50919 (1982-03-01), None
patent: 58-134028 (1983-08-01), None
patent: 09183730 (1997-07-01), None
patent: WO 00/35461 (2000-06-01), None
patent: WO 02/074247 (2002-09-01), None
patent: WO 02074247 (2002-09-01), None
patent: WO 03/035030 (2003-05-01), None
Takahashi, Kohki; Kanno, Harushige; Synergistic Activities of Combinations of beta-Lactams, Fosfomycin, and Tobramycin AgainstPseudomonas aeruginosa; 1984; American Soc. for Microbiology; Antimicrobial Agents and Chemotherapy, Nov. 1984, vol. 26, No. 5, pp. 789-791.
Martinez-Martinez, Luis; Rodriguez, Guadalupe; Pascual, Alvaro; Suarez, Ana Isabel; Perea, Evelio J.; In-vitro activity of antimicrobial agent combinations against multiresistant acinetobacter baumannii; 1996; The British Society for Antimicrobial Chemotherapy; Journal of Antimicrobial Chemotherapy, vol. 38, pp. 1107-1108.
Mackay, M.L.; Milne, K.; Gould, I.M.; “Comparison of methods for assessing synergic antibiotic interactions,” 2000, Elsevier; Antimicrobial Agents, vol. 15, pp. 125-129.
Isenberg, Henry D.; Alperstein, Phyllis; France, Kenneth; “In vitro Activity of Ciprofloxacin, Levofloxacin, and Trovafloxacin, Alone and in Combination with β-Lactams, against Clinical Isolates ofPseudomonas aeruginosa, [. . . ],” 1999, Elsevier; Diagonstic Microbiology and Infectious Disease, vol. 33, No. 2, pp. 81-86.
National Heart Lung and Blood Institute information on cystic fibrosis, retrieved from <www.nhlbi.nih.gov/health/dci/Diseases/cf> on Sep. 11, 2010, pp. 1-11.
The Cystic Fibrosis Foundation Frequently Asked Questions about cystic fibrosis, retrieved from <www.cff.org/AboutCF/Faqs> on Sep. 11, 2010, pp. 1-5.
MacLeod et al., “Antibacterial Activities of a Fosfomycin: Tobramycin Combination (GS-9310/11) Against Pathogens Commonly Found in CF and Bronchiectasis”, Poster No. 328, 21stAnnual North American Cystic Fibrosis Conference, Oct. 3-6, 2007, Anaheim, California.
Anwar, H. et al. (1990) “Enhanced Activity of Combination of Tobramycin and Piperacillin for Eradication of Sessile Biofilm Cells ofPseudomonas aeruginosa,” Antimicrobial Agents and Chemotherapy34(9):1666-1671.
Daza, R, et al. (1977) “Interactions of Fosfomycin with other Antibiotics,”Chemotherapie23(Suppl). 1):86-92.
Emerson, J. et al. (2010) “Changes in Cystic Fibrosis Sputum Microbiology in the United States Between 1995 and 2008,”Pediatric Pulmonology45:363-370.
Hoiby, N. (2002) “New antimicrobials in the management of cystic fibrosis,”Journal of Antimicrobial Chemotherapy49:235-238.
Isenberg, H. et al. (1999) “In Vitro Activity of Ciprofloxacin, Levofloxacin, and Trovafloxacin, Alone and in Combination withβ-Lactams, against Clinical Isolates ofPseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia ,” Diagn Microbiol Infect Dis. 33:81-86.
Landry, R. et al. (2006) “Mucin-Pseudomonas aeruginosainteractions promote biofilm formation and antibiotic resistance,”Molecular Microbiology59(1):142-151.
Levy, J. (1983) “Bioactivity of Gentamicin in Purulent Sputum from Pattens with Cystic Fibrosis or Bronchiectasis: Comparison with Activity in Serum,” 118:1069-1076.
Levy, J. (1986) Antibiotic Activity in Sputum,J. Pediatric108(2):841-846.
MONUROL® Label, Rev. Jul. 2007.
Ohtani, I. et al. (1985) “Protective Effect of Fosfomycin against Aminoglycoside Ototoxicity,”ORL47:42-48.
Rodriguez-Rojas, A. et al. (2010) “Assessing the Emergence of Resistance: The Absence of Biological Cost In Vivo Compromise Fosfomycin Treatments forP. aeruginosaInfections,”PLoS ONEwww.plosone.org 5(4):e10193 doi:10/1371/journal.pone.0010193.
TOBI® Label Rev. Jul. 2008, Printed in USA 5001770.
Vishwanath, S. et al. (1987) “Effects of subminimal inhibitory concentration of antibodies on the adherence ofPseudomonas aeruginosato tracheobronchial mucin,”Journal of Antimicrobial Chemotherapy19:579-583.
Yanagihara, K. et al. (2000) “Combination therapy for chronicPseudomonas aeruginosarespiratory infection associated with biofilm formation,”Journal of Antimicrobial Chemotherapy46:69-72.
Yassien, M. et al. (1995) “Modulation of Biofilms ofPseudomonas aeruginosaby Quinolones,” Antimicrobial Agents and Chemotherapy 39(10):2262-2268.
Japanese Office Action issued Jun. 14, 2010.
Aaron, “Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms”, Pediatric Respiratory Reviews (2007) 8, pp. 256-261.
Borowski et al., “Studies on the combined action of phosphonomycin with streptomycin, penicillin G and ampicillin”, Archivum Immunologiae et Therapiae Experimentalis 1976, 24, pp. 191-195.
Borowski et al., “Combined action of fosfomycin with β-Lactam and aminoglycoside antibiotics”, Chemotherapy 23 (Suppl. 1): 1977, pp. 82-85.
Bugnon et al., “Bactericidal effect of pefloxacin and fosfomycin againstPseudomonas aeruginosain a rabbit endocarditis model with pharmacokinetics of pefloxacin in humans simulated in vivo”, Eur. J. Clin. Microbiol. Infect. Dis., 1997, 16, pp. 575-580.
Buisson et al., “[Preliminary study of the antagonistic effects between fosfomycin and beta-lactams onPseudomonas aeruginosaobserved on the antibiogram]”Pathyol Biol. (Paris), Jun. 1988; 36 (5 Pt 2): 671-4.
Chin et al., “Synergy of fosfomycin with beta-lactam antibiotics against staphylococci and aerobic gram-negative bacilli”, Drugs Exptl. Clin. Res. XII(12) 1986, pp. 943-947.
Dubrous et al., “[Sensitivity to fosfomycin of multiresistant serotype 012Pseudomonas aeruginosa. Multicenter study]”, Pathol. Biol. (Paris), Jun. 1997; 45(6), 472-8.
Eliopoulos et al., “Antibiotic combinations: should they be tested?”, Clinical Microbiology Reviews, Apr. 1988, vol. 1, No. 2 pp. 139-156.
Ferrara et al., “Effect of different combinations of sparfloxacin, oxacillin, and fosfomycin against methicillin-resistant staphylococci”, Eur. Journal Clin. Microbiol. Infect. Dis., vol. 16, 1997 Notes pp. 535-537.
Figueredo et al., “Synergy of ciprofloxacin with fosfomycin in vitro againstPseudomonasisolates from patients with cystic fibrosis”, Journal of Antimicrobial Chemotherapy, 1988 22, pp. 41-50.
Hayami et al., “Activities of β-lactams, fluoroquinolones, amikacin and fosfomycin alone and in combination againstPseudomonas aeruginosaisolated from complicated urinary tract infections”, J. Infect Chemother. 1999 5, pp. 130-138.
Hunt et al., “Macromolecular mechanisms of spu
Baker William
MacLeod David
Gilead Sciences, Inc.
Greene Ivan
Wood Phillips Katz Clark & Mortimer
Woodward Cherie M
LandOfFree
Aerosolized fosfomycin/aminoglycoside combination for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aerosolized fosfomycin/aminoglycoside combination for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aerosolized fosfomycin/aminoglycoside combination for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2677570